These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24052572)

  • 1. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
    Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
    J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
    Aichberger KJ; Gleixner KV; Mirkina I; Cerny-Reiterer S; Peter B; Ferenc V; Kneidinger M; Baumgartner C; Mayerhofer M; Gruze A; Pickl WF; Sillaber C; Valent P
    Blood; 2009 Dec; 114(26):5342-51. PubMed ID: 19850739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional and biological analysis of Bcl-xL expression in human osteosarcoma.
    Wang ZX; Yang JS; Pan X; Wang JR; Li J; Yin YM; De W
    Bone; 2010 Aug; 47(2):445-54. PubMed ID: 20580954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
    Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
    Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
    Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.
    Trudel S; Li ZH; Rauw J; Tiedemann RE; Wen XY; Stewart AK
    Blood; 2007 Jun; 109(12):5430-8. PubMed ID: 17332241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Son MP; Patel H; Peterson D; Attkisson E; Fisher RI; Friedberg JW; Dent P; Grant S
    Mol Cancer Ther; 2012 May; 11(5):1122-32. PubMed ID: 22411899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
    Mazumder S; Choudhary GS; Al-Harbi S; Almasan A
    Cancer Res; 2012 Jun; 72(12):3069-79. PubMed ID: 22525702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
    Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
    Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
    Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
    Aichberger KJ; Mayerhofer M; Gleixner KV; Krauth MT; Gruze A; Pickl WF; Wacheck V; Selzer E; Müllauer L; Agis H; Sillaber C; Valent P
    Blood; 2007 Apr; 109(7):3031-41. PubMed ID: 17110460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
    Gleixner KV; Rebuzzi L; Mayerhofer M; Gruze A; Hadzijusufovic E; Sonneck K; Vales A; Kneidinger M; Samorapoompichit P; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Sillaber C; Willmann M; Valent P
    Exp Hematol; 2007 Oct; 35(10):1510-21. PubMed ID: 17681669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
    Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
    Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
    Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
    Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
    Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim.
    Nguyen M; Cencic R; Ertel F; Bernier C; Pelletier J; Roulston A; Silvius JR; Shore GC
    BMC Cancer; 2015 Aug; 15():568. PubMed ID: 26231047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
    Gleixner KV; Peter B; Blatt K; Suppan V; Reiter A; Radia D; Hadzijusufovic E; Valent P
    Haematologica; 2013 Sep; 98(9):1450-7. PubMed ID: 23539538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
    Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M
    Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.